STOCKHOLM, Sweden and SOUTH SAN FRANCISCO, Calif., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) and Hyperion Therapeutics, Inc., (Nasdaq:HPTX) announced today that Sobi has been granted the exclusive rights by Hyperion to distribute RAVICTI (glycerol phenylbutyrate) Oral Liquid on a named patient basis for the chronic treatment of Urea Cycle Disorders (UCD) in the Middle East. Under the agreement, Sobi receives the rights to provide RAVICTI in Saudi Arabia, Oman, United Arab Emirates, Jordan, Kuwait, Qatar and Bahrain. Financial details were not disclosed.
Sobi Gains Rights To Distribute RAVICTI(R) On A Named Patient Use Basis In Middle East From Hyperion Therapeutics, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.